Molecular modeling and synthesis of inhibitors of herpes simplex virus type 1 uracil-DNA glycosylase

Journal of Medicinal Chemistry

Volumn 42, Issue 13, 1999, Pages 2344-2350

  Sun, Hongmao ^a,d   Zhi, Chengxin ^a   Wright, George E ^a   Ubiali, Daniela ^b   Pregnolato, Massimo ^b   Verri, Annalisa ^c   Focher, Federico ^c   Spadari, Silvio ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

^c CNR   (Italy)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 HYDROXYETHYL) 6 (4 HEXYLANILINO)URACIL; 1 (2 HYDROXYETHYL) 6 (4 OCTYLANILINO)URACIL; 1 (3 HYDROXYPROPYL) 6 (4 HEXYLANILINO)URACIL; 6 (4 OCTYLANILINO)URACIL; 6 (4 OCTYLPHENOXY)URACIL; ANTIVIRUS AGENT; ENZYME INHIBITOR; UNCLASSIFIED DRUG; URACIL DNA GLYCOSYLTRANSFERASE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; HERPES SIMPLEX VIRUS 1; HYDROPHILICITY; MOLECULAR INTERACTION; MOLECULAR MODEL; STRUCTURE ANALYSIS; VIRUS LATENCY;

ANILINE COMPOUNDS; DNA GLYCOSYLASES; DRUG DESIGN; ENZYME INHIBITORS; HERPESVIRUS 1, HUMAN; HUMANS; MODELS, MOLECULAR; N-GLYCOSYL HYDROLASES; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; URACIL; URACIL-DNA GLYCOSIDASE;

EID: 0033168486     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980718d     Document Type: Article

References (27)

1. Wildy, P.; Field, H. J.; Nash, A. A. Classical Herpes Latency Revisited. In Virus Persistence; Mahy, B. W. H., Minson, A. C., Darby, G. K., Eds.; Cambridge University Press: Cambridge, 1982; pp 134-167.
2. Price, R. W. Herpes Simplex Virus Latency: Adaptation to the Peripheral Nervous System. I. Cancer Invest. 1985, 3, 285-292; II. ibid. 389-403.
3. Price, R. W. Herpes Simplex Virus Latency: Adaptation to the Peripheral Nervous System. I. Cancer Invest. 1985, 3, 285-292; II. ibid. 389-403.
4. Roizman, B.; Sears, A. E. An Inquiry into the Mechanisms of Herpes Simplex Virus Latency. Annu. Rev. Microbiol. 1987, 41, 543-571.
5. Ho, D. Y. Herpes Simplex Virus Latency: Molecular Aspects. Prog. Med. Virol. 1992, 39, 76-115.
6. Klein, R. J.; DeStefano, E.; Friedman-Kien, A. E.; Brady, E. Effect of Acyclovir on Latent Herpes Simplex Virus Infections in Trigeminal Ganglia of Mice. Antimicrob. Agents Chemother. 1981, 19, 937-939.
7. Mattison, H. R.; Reichman, R. C.; Benedetti, J.; Bolgiano, D.; Davis, L. G.; Bailey-Farchione, A.; Remingon, M.; Winter, C.; Corey, L. Double-blind, Placebo-controlled Trial Comparing Long-Term Suppressive Therapy with ShortOLINIT-Term Oral Acyclovir Therapy for the Management of Recurrent Genital Herpes. Am. J. Med. Suppl. 1988, 2A 85, 20-25.
8. Verri, A.; Mazzarello, P.; Biamonti, G.; Spadari, S.; Focher, F. The Specific Binding of Nuclear Protein(s) to the cAMP Responsive Element (CRE) Sequence (TGACGTCA) is Reduced by the Misincorporation of U and Increased by the Deamination of C. Nucleic Acids Res. 1990, 18, 5775-5780.
9. Pyles, R. B.; Thompson, R. L. Evidence that the Herpes Simplex Virus Type 1 Uracil DNA Glycosylase Is Required for Efficient Viral Replication and Latency in the Murine Nervous System. J. Virol. 1994, 68, 4963-4972.
10. Focher, F.; Mazzarello, P.; Verri, A.; Hübscher, U.; Spadari, S. Activity Profiles of Enzymes that Control the Uracil Incorporation into DNA During Neuronal Development. Mutat. Res. 1990, 237, 73-75.
11. Focher, F.; Verri, A.; Spadari, S.; Manservigi, R.; Gambino, J.; Wright, G. E. Herpes Simplex Virus Type I Uracil-DNA Glycosylase: Isolation and Selective Inhibition by Novel Uracil Derivatives. Biochem. J. 1993, 292, 883-889.
12. Caradonna, S. J.; Cheng, Y. C. Induction of Uracil-DNA Glycoaylase and dUTP Nucleotidohydrolase Activity in Herpes Simplex Virus-Infected Human Cells. J. Biol. Chem. 1981, 256, 9834-9837.
13. Savv, R.; McAuley-Hecht, K.; Brown, T.; Pearl, L. The Structural Basis of Specific Base-Excision by Uracil-DNA Glycosylase. Nature 1995, 373, 487-493.
14. Savva, R.; Pearl, L. Personal communication.
15. Verlinde, C. L.; Hol, W. G. Structure-based Drug Design: Progress, Results and Challenges. Structure 1994, 2, 577-587.
16. Slupphaug, G.; Mol, C. D.; Kavli, B.; Arval, A. S.; Krokan, H. E.; Tainer, J. A. A Nucleotide-flipping Mechanism from the Structure of Human Uracil-DNA Glycosylase Bound to DNA. Nature 1996, 384, 87-92.
17. Blokzijl, W.; Engberts, J. B. F. N. Hydrophobic Effects. Opinions and Facts. Angew. Chem., Int. Ed. 1993, 32, 1545-1579.
18. Mol, C. D.; Arval, A. S.; Slupphaug, G.; Kavli, B.; Alseth, I.; Krokan, H. E.; Tainer, J. A. Crystal Structure and Mutational Analysis of Human Uracil-DNA Glycosylase: Structural Basis for Specificity and Catalysis. Cell 1995, 80, 869-878.
19. 2-phenylguanine Derivatives as Inhibitors of Herpes Simplex Virus Thymidine Kinases. J. Med Chem. 1995, 38, 49-57.
20. 2-phenylguanine (HBPG), a Thymidine Kinase Inhibitor, Suppresses Herpes Virus Reactivation in Mice. Antiviral Res. 1996, 30, 87-94.
21. 2-phenylguanine (HBPG), a Thymidine Kinase Inhibitor, on Clinical Recurrences of Ocular Herpes Keratitis in Squirrel Monkeys. Antiviral Res. 1996, 33, 65-72.
22. Wright, G. E.; Brown, N. C. Inhibitors of Bacillus Subtilis DNA Polymerase III. 6-Anilinouracils and 6-(Alkylamino)uracils. J. Med. Chem. 1980, 23, 34-38.
23. Baker, B. R.; Rzeszotarski, W. Irreversible Enzyme Inhibitors CIV. Inhibitors of Thymidine Phosphorylase VIII. Further Studies on Hydrophobic Bonding with 6-Substituted Uracils. J. Med. Chem. 1967, 10, 1109-1113.
24. Traube, W. Der synthesizche Aufbau der Harnsäure, des Xanthins, Theobromins, Theophyllins und Caffeïns aus der Cyanessigsäure. Chem. Ber. 1900, 33, 3035-3056.
25. Biltz, H.; Peukert, E. 3-Äthyl-harnsäure und 3-Äthyl-xanthin. Chem. Ber. 1925, 58, 2190-2199.
26. Whitehead, C. W.; Traverso, J. J. Exchange Amination. Alkyl and Arylaminopyrimidines and Purines. J. Am. Chem. Soc. 1960, 82, 3971-3974.
27. Jung, M. E.; Lyster, M. A. Quantitative Dealkylation of Alkylethers via Treatment with Trimethylsilyl Iodide. J. Org. Chem. 1977, 42, 3761-3764.